Cervical cancer
Reading File
Finding Sources
Searching PubMed
"cervical cancer"[MeSH Terms] AND management
Searching the Web
cervical cancer 2025 2026 updated guidelines treatment
Reading File
Reading File
Searching PubMed
"cervical cancer" AND treatment
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information to deliver a thorough, well-structured response on cervical cancer. Let me compile it.
Cervical Cancer
Epidemiology
Cervical cancer is the third most common gynecologic cancer in the United States, with over 14,000 new cases and 4,000 deaths annually. Globally, it remains a major killer - particularly in Central/South America and Africa - due to inadequate access to screening and treatment. The incidence in developed countries has fallen by more than 80% since the 1950s, largely because of the Papanicolaou (Pap) test and HPV screening. The median age at diagnosis is 48 years.
- Goldman-Cecil Medicine, p. 2088
Etiology and Pathobiology
HPV is the central cause - detected in >99% of cervical cancers.
- Over 200 HPV strains exist; ~40 infect the genital tract
- Low-risk HPV (e.g. HPV 6, 11): causes genital warts
- High-risk HPV (e.g. HPV 16, 18): causes cervical, vaginal, vulvar, anal, penile, oral, and throat cancers
- HPV 16 + 18 account for 70% of cervical cancers
- HPV 31, 33, 45, 52, 58 account for an additional 20%
Molecular mechanism:
-
HPV is a small, non-enveloped, double-stranded DNA virus
-
Infects basal cells at the squamocolumnar junction (transformation zone)
-
Oncoproteins E6 and E7 are the key drivers:
- E6 binds and degrades p53 (tumor suppressor) - inhibits apoptosis
- E7 binds and degrades pRB (retinoblastoma protein) - disrupts cell cycle regulation; also targets cyclins and CDKs
- Both have immunosuppressive effects enabling immune evasion
-
Most HPV infections are transient and clear within 1-2 years
-
In ~10% of women, persistent infection develops - this is necessary for carcinogenesis
-
Carcinogenic progression takes approximately a decade to develop into malignancy
-
Goldman-Cecil Medicine, p. 2089
Risk Factors
| Risk Factor |
|---|
| HPV infection (core) |
| Early onset of sexual activity |
| Multiple sexual partners |
| History of genital warts |
| Multiparity |
| Lower socioeconomic status |
| Cigarette smoking |
| Long-term oral contraceptive use (>5 years) |
| HIV infection / immunodeficiency |
| In utero DES exposure |
| Hispanic and Black American women (disparities) |
- Goldman-Cecil Medicine, Table 184-1
Histopathology and Precursor Lesions
| Dysplasia Term | CIN Equivalent | Bethesda (Pap Cytology) |
|---|---|---|
| Very mild - Mild | CIN 1 | LSIL |
| Moderate | CIN 2 | HSIL |
| Severe / Carcinoma in situ | CIN 3 | HSIL |
| Invasive carcinoma | - | - |
- CIN = Cervical Intraepithelial Neoplasia
- LSIL = Low-Grade Squamous Intraepithelial Lesion
- HSIL = High-Grade Squamous Intraepithelial Lesion
- Goldman-Cecil Medicine, Table 184-3
Histologic types of invasive cervical cancer:
- Squamous cell carcinoma - most common (~70%)
- Adenocarcinoma - less common but increasing in incidence; harder to detect by cytology
Clinical Manifestations
Early stage: Largely asymptomatic - detected by screening.
Advanced disease:
- Post-coital or irregular vaginal bleeding
- Vaginal discharge (watery or blood-tinged)
- Pelvic pain
- Dyspareunia (pain with intercourse)
- Bowel/bladder dysfunction (urinary obstruction, hematuria, rectal bleeding) - from local invasion
Spread pattern: Local extension to uterine corpus, vagina, bladder, and parametria; lymphatic and hematogenous dissemination in advanced disease.
- Goldman-Cecil Medicine, p. 2089
Diagnosis and Staging
Diagnosis: Colposcopy + biopsy (directed by abnormal screening). Direct biopsy of visible lesions in advanced cases. Pap smear is NOT adequate for diagnosis once an obvious lesion is visible.
Staging (FIGO system): Clinical + radiographic + pathological.
- Workup: pelvic and rectovaginal exam, examination under anesthesia, cystoscopy, proctoscopy, MRI, CT, PET scan
- Managed by gynecologic oncologist
Treatment by Stage
| Stage | Description | Treatment |
|---|---|---|
| Microscopic disease | Detected only on biopsy | Conization (cone biopsy) or LEEP - may be sufficient |
| Low-volume, cervix-limited | Small tumor, no spread | Radical hysterectomy (OPEN surgery - better disease-free survival than minimally invasive); simple hysterectomy in very low-risk cases |
| Fertility-sparing option | Selected low-stage patients | Radical trachelectomy (cervix removal only) |
| Post-surgical adverse features | LVSI, deep stromal invasion, large tumor, positive margins, parametrial/nodal involvement | Adjuvant radiation therapy |
| Stage IIB-IVA (locally advanced) | Parametrial or pelvic extension | Definitive chemoradiation: weekly cisplatin + radiation |
| Metastatic / recurrent | Distant disease | Platinum-taxane doublet + bevacizumab (anti-VEGF); add pembrolizumab (anti-PD-L1) if PD-L1-positive |
| Central pelvic recurrence (selected) | Post-treatment relapse | Pelvic exenteration - 25-50% cure rate |
Key points:
-
Open (not laparoscopic/robotic) radical hysterectomy gives better disease-free survival for early cervical cancer
-
Bevacizumab provides incremental survival benefit in advanced disease
-
Pembrolizumab (immune checkpoint inhibitor) is used in PD-L1-expressing tumors
-
Goldman-Cecil Medicine, pp. 2089-2090
Screening
| Test | Details |
|---|---|
| Pap smear | Detects abnormal cervical cytology; used from age 21 |
| HPV co-testing | High-risk HPV DNA; preferred in women 30-65 every 5 years |
| Combined Pap + HPV | Every 5 years, ages 30-65 |
| Pap alone | Every 3 years, ages 21-65 |
Prevention: HPV Vaccination
-
Routine vaccination at ages 11-12 years (can start at age 9)
-
Two-dose series (6-12 months apart) if started before age 15
-
Also indicated for previously unvaccinated adults up to age 45
-
Males should be vaccinated to prevent HPV spread and HPV-associated head/neck cancers
-
Only the nine-valent HPV vaccine is currently available in the US
-
Efficacy >97% in preventing HPV-related disease in vaccine recipients
-
Reduction in cervical cancer incidence:
- 87% for vaccination at age 12-13
- 62% for age 14-16
- 34% for age 16-18
-
Vaccination after treatment for CIN 2/3 may decrease recurrence
-
Goldman-Cecil Medicine, pp. 2090-2091
Recent Evidence (2025)
A 2025 Cochrane network meta-analysis on HPV vaccination (PMID 41276263) confirmed that HPV vaccines are highly effective for preventing cervical cancer and other HPV-related diseases across multiple vaccine formulations. Additionally, a 2025 Cochrane review (PMID 40919695) examined HPV vaccination in women who have undergone conisation, supporting its use to reduce recurrence risk.
Summary
Cervical cancer is almost entirely preventable through HPV vaccination and treatable when caught early by screening. The disease is driven by persistent high-risk HPV infection (especially types 16 and 18) that disrupts p53 and pRB tumor suppressors. Early disease is managed surgically; locally advanced disease requires chemoradiation with cisplatin; metastatic disease is treated with platinum-taxane chemotherapy plus bevacizumab and/or pembrolizumab.
Ovarian hyper stimulation syndrome
Reading File
Finding Sources
Searching PubMed
"ovarian hyperstimulation syndrome"[MeSH Terms] AND management
Reading File
Reading File
Reading File
Finding Sources
Reading File
I now have comprehensive, well-structured content from Berek & Novak's Gynecology and Tintinalli's Emergency Medicine. Here is the full response:
Ovarian Hyperstimulation Syndrome (OHSS)
Definition
OHSS is a completely iatrogenic medical complication unique to stimulatory infertility treatment. It results from ovarian enlargement and fragility, combined with fluid shifts from the intravascular to extravascular space - producing intravascular volume depletion alongside third-space fluid accumulation.
- Berek & Novak's Gynecology, p. 2100
Pathophysiology
The hallmark is increased capillary permeability leading to protein-rich fluid extravasation. Key mediators:
- VEGF (Vascular Endothelial Growth Factor): Expressed in granulosa cells and augmented by hCG - primary driver of vascular permeability
- Angiotensin: Elevated renin and prorenin in follicular fluid increase capillary permeability
- Inflammatory cytokines: Multiple pro-inflammatory mediators contribute
- hCG (exogenous or endogenous from early pregnancy) is the central trigger
The result is massive transudation of albumin and fluid into the peritoneal, pleural, and sometimes pericardial cavities.
- Berek & Novak's Gynecology, p. 2100; Tintinalli's Emergency Medicine
Onset Patterns
| Type | Timing | Cause | Severity |
|---|---|---|---|
| Early OHSS | 3-7 days after hCG trigger | Exogenous hCG administration | Usually self-limiting |
| Late OHSS | 12-17 days after hCG trigger | Endogenous hCG from early pregnancy | Tends to be more severe; worsened by multiple gestation |
- Berek & Novak's Gynecology, p. 2100
Severity Classification (Golan/Navot Criteria)
| Grade | Classification | Features |
|---|---|---|
| Grade 1 (Mild) | Mild OHSS | Abdominal distention and discomfort |
| Grade 2 (Mild) | Mild OHSS | + Nausea, vomiting, or diarrhea; ovary diameter ≥5 mm |
| Grade 3 (Moderate) | Moderate OHSS | + Sonographic subclinical ascites near liver or pelvis (pocket >9 mm) |
| Grade 4 (Severe) | Severe OHSS | + Clinical ascites, hydrothorax, or dyspnea |
| Grade 5 (Severe) | Severe OHSS | + Hemoconcentration, renal insufficiency/oliguria, elevated transaminases, VTE, or ARDS |
- Berek & Novak's Gynecology, p. 2100
Risk Factors
Patient-related:
- Polycystic ovary syndrome (PCOS)
- Polycystic ovarian morphology
- Elevated anti-Mullerian hormone (AMH) >3.36 ng/mL
- Previous episode of OHSS
Stimulation-related:
- E2 >3,500 pg/mL at hCG trigger: 1.5% incidence of severe OHSS
- E2 >6,000 pg/mL at hCG trigger: 38% incidence of severe OHSS
- >20 preovulatory follicles: 15% incidence of severe OHSS
- 20-29 oocytes retrieved: 1.4% severe OHSS
- ≥30 oocytes retrieved: 22.7% severe OHSS
Severe OHSS occurs in ~5% of GnRH antagonist protocols and ~9% of GnRH agonist protocols.
- Berek & Novak's Gynecology, p. 2100
Clinical Features
Symptoms: Abdominal bloating (most common initial symptom), nausea, vomiting, diarrhea, dyspnea, decreased urine output.
Severe disease:
- Tense ascites
- Pleural effusion / hydrothorax
- Pericardial effusion (rare)
- Oliguria progressing to renal failure
- Hemoconcentration (raised hematocrit)
- Hyponatremia, hyperkalemia
- Elevated liver transaminases
Life-threatening complications (thromboembolism - most feared):
-
Jugular, subclavian, retinal, extremity venous thrombosis
-
Cerebral venous thrombosis
-
Stroke (arterial)
-
STEMI
-
Pulmonary embolism
-
Sepsis, ARDS
-
Tintinalli's Emergency Medicine
Management
Outpatient (Mild-Moderate)
- Limit activity
- Weigh daily (hospitalize if weight gain >2 lb/day)
- Fluid intake ≥1 L/day of electrolyte-balanced fluids
- Monitor fluid intake and urine output
- Daily telephone or clinic follow-up
Indications for Hospitalization
- Inability to tolerate oral hydration
- Hemodynamic instability
- Respiratory compromise
- Tense ascites
- Hemoconcentration
- Leukocytosis
- Hyponatremia or hyperkalemia
- Abnormal renal or liver function
- Decreased oxygen saturation
Inpatient / ICU Management
| Intervention | Details |
|---|---|
| IV fluids | Essential for hypovolemia, hypotension, electrolyte correction, oliguria - even though they may worsen ascites |
| Albumin 25% | 50-100 mg IV every 4-12 hours for further intravascular expansion if needed |
| Diuretics | Only AFTER hypovolemia is corrected |
| Thromboembolism prophylaxis | Mandatory (anticoagulation) |
| Paracentesis | Transvaginal or transabdominal ultrasound-guided; relieves pain, hydrothorax, persistent oliguria; rapid large-volume removal is generally safe in this young population with monitoring |
| ICU admission | If hyperkalemia, renal failure, respiratory failure, or thromboembolic disease |
- Berek & Novak's Gynecology, p. 2101
Prevention
1. Identify High-Risk Patients
PCOS, AMH >3.4 ng/mL, peak E2 >3,500 pg/mL, ≥25 follicles developing, ≥24 oocytes expected.
2. Stimulation Protocol Modifications
- Use lower starting gonadotropin doses (150-225 IU) in high-risk patients
- Prefer GnRH antagonist protocols over agonist protocols - reduces total dose/duration
- GnRH antagonists introduced after oocyte retrieval can accelerate regression of early OHSS
3. Ovulation Triggering
- GnRH agonist trigger (instead of hCG) in antagonist cycles: induces endogenous LH surge with very short half-life, reducing OHSS risk - preferred for patients not doing fresh transfer
- Low-dose hCG co-administered with GnRH agonist trigger: preserves pregnancy rates while reducing OHSS risk for fresh transfer cycles
4. Coasting
- Indicated when E2 >4,500 pg/mL and/or 15-30 mature follicles
- Withhold gonadotropins; check E2 daily
- Trigger when E2 falls to <3,500 pg/mL
- Cycle cancellation if: >30 mature follicles, coast duration >4 days, or E2 rises to >6,500 pg/mL during coast
5. Adjunctive Medications
| Drug | Mechanism / Role |
|---|---|
| Cabergoline (0.5 mg/day × 8 days from hCG day) | Dopamine agonist - inhibits VEGF production; reduces OHSS rates; avoid long-term use (valvular heart disease risk) |
| Metformin (in PCOS patients) | Reduces OHSS rates |
| Letrozole (post-hCG trigger) | Effective in preventing moderate-to-severe early-onset OHSS |
| Aspirin | Decreases OHSS risk as adjunct |
| Calcium | Decreases OHSS risk as adjunct |
| Albumin | Benefit in decreasing OHSS rates is unclear |
6. Embryo Cryopreservation (Freeze-All Strategy)
- Cryopreserving all embryos without fresh transfer reduces late-onset OHSS
- Early-onset OHSS may still occur
- Live birth rates after frozen-thaw transfer are comparable to fresh transfer with modern freezing techniques
7. In Vitro Oocyte Maturation (IVM)
-
Aspirates immature follicles without gonadotropin stimulation, then matures oocytes in vitro
-
Completely avoids ovarian stimulation and therefore OHSS
-
Still considered experimental; only in specialized centers
-
Berek & Novak's Gynecology, pp. 2101-2103
Recent Evidence (2025)
- A 2025 Cochrane network meta-analysis (PMID 40590303) on controlled ovarian stimulation protocols for ART provides updated comparative data on protocol strategies, informing OHSS risk reduction choices.
- A 2025 meta-analysis (PMID 40826343) on risk prediction models for OHSS identified key predictive factors that can guide individualized risk stratification - consistent with the AMH, antral follicle count, and E2 thresholds discussed above.
Summary
OHSS is driven by hCG-stimulated VEGF release causing capillary leak, fluid third-spacing, and intravascular depletion. Mild disease is common and self-limiting; severe disease involves ascites, pleural effusion, hemoconcentration, and life-threatening thromboembolism. Management hinges on careful fluid replacement, albumin, anticoagulation, and paracentesis when needed. Prevention focuses on identifying high-risk patients (PCOS, high AMH, high E2), modifying stimulation protocols, using GnRH agonist triggers, coasting, cabergoline, and the freeze-all embryo strategy.
This is a shared conversation. Sign in to Orris to start your own chat.